Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigert mRNA in blood and bone marrow

Clinical Chemistry

Volumn 43, Issue 3, 1997, Pages 443-452

  Corey, Eva ^a   Arfman, Edward W ^a   Liu, Alvin Y ^a   Vessella, Robert L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; metastasis; peripheral blood mononuclear cells

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD; BONE MARROW; CANCER DIAGNOSIS; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOLECULAR CLONING; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031050893     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.3.443     Document Type: Article

References (45)

1. Wang X, Heller R, Van Voorhis N, Cruse CW, Glass F, Fenske N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-74.
2. Miyajima Y, Kato K, Numata S, Horibe K. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1995;75:2757-61.
3. Komeda T, Fukuda Y, Sando T, Kita R, Fukura M, Nishida N, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood. Cancer 1995;75:2214-9.
4. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994;12:475-82.
5. Hamdy FC, Lawry J, Anderson JB, Parsons MA, Rees RC, Williams JL. Circulating prostate-specific antigen positive cells correlates with metastatic prostate cancer. Br J Urol 1992;69:392-6.
6. Deguchi T, Doi T, Ehara H, Ito S, Takahashi Y, Nishino Y, et al. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1993;53:5350-4.
7. Israeli RS, Miller WH Jr, Su SL, Powell T, Fair WR, Samadi DS, et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994;54:6306-10.
8. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994;43: 765-75.
9. Seiden MV, Gaynes L, Kaplan I, Krithivas K, Propert K, Bryant M, et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994;12:2634-9.
10. Wood DP Jr, Banks ER, Humphreys S, McRoberts JW, Rangnekar VM. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994;74:2533-40.
11. Smith MR, Biggar S, Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells - implication for detection of micrometastasis. Cancer Res 1995;55:2640-4.
12. Ghossien RA, Scher HI, Gearld WL, Kelly WK, Amsterdam A, Zhang ZF, Rosai J. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma - clinical implications. J Clin Oncol 1995;13:1195-200.
13. Loric S, Dumas F, Eschwege P, Blanchet P, Benoit G, Jardin A, Lacour B. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem 1995; 41:1698-704.
14. Galvan B, Christipoulos TK, Diamandis EP. Detection of prostate-specific antigen mRNA by reverse transcription polymerase chain reaction and time-resolved fluorometry. Clin Chem 1995;41: 1705-9.
15. Katz AE, De Vries GM, Begg MD, Raffo AJ, Cama C, O'Toole K, et al. Enhanced reverse transcriptase polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995;75:1642-8.
16. O'Hara MS, Veltri RW, Skirpstunas P. Basal PSA mRNA levels detected by quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR-PSA) in blood from subjects without prostate cancer [Abstract]. J Urol 1996;155(Suppl):430A.
17. Slawin K, Song W, Gottenger RL, Kattan M, O'Hara MS, Wang D, Veltri RW. Comparison of results obtained using different RT-PCR PSA assay methods on a single set of clinical specimens [Abstract]. J Urol 1996;155(Suppl):425A.
18. Sokollof M, Tso CL, Franklin J, Nelson S, Dorey F, de Kernion J, et al. Quantitative polymerase chain reaction (PCR) does not improve prostate cancer (PC) staging: a clinical-pathologic-molecular analysis of 121 patients [Abstract]. J Urol 1996;155(Suppl):428A.
19. De Vries GM, Olsson CA, Benson MC, Connor JP, Buttyan R, Katz AE. Qualitative and quantitative RT-PCR for PSA: molecular staging of prostate cancer [Abstract]. J Urol 1996;155(Suppl):426A.
20. Ignatoff JM, Oefelein MG, Hertz B, Watkin W, Kaul KL. Prostate specific antigen (PSA) reverse transcriptase-polymerase chain reaction (RT-PCR) assay in preoperative staging of prostate cancer [Abstract]. J Urol 1996;155(Suppl):427A.
21. Wood DP Jr, Weinstein M, Humphriess S, Rangnekar VM. Prognostic significance of circulating prostate cells [Abstract]. J Urol 1996;155(Suppl):429A.
22. Ellis WJ, Vessella RL, Corey E, Arfman EW, Oswin M, Melchior SW, Lange PH. Use of a reverse transcriptase polymerase chain reaction (RT-PCR) to detect prostate cells in the blood [Abstract]. J Urol 1996;155(Suppl):272A.
23. Melchior SW, Corey E, Ellis WJ, Ross AA, Arfman EW, Oswin M, et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate (CaP) [Abstract]. J Urol 1996; 155(Suppl):972A.
24. Moreno JG, Long JP, O'Hara M, Veltri RW, Alexander A, Shupp-Byrne D, Gomella G. Surgical prostatic instrumentation causes showering of prostate cells into the circulation as determined by RT-PCR of PSA [Abstract], J Urol 1996;155(Suppl):970A.
25. Cama CL, Olsson CA, Buttyan R, Wise GJ, De Vries G, Katz AE. Molecular staging of prostate cancer III. Effects of digital rectal examination, cytoscopy, and needle biopsy on the enhanced reverse transcriptase polymerase chain reaction assay [Abstract]. J Urol 1996;155(Suppl):971A.
26. Olsson CA, De Vries GM, Raffo AJ, Benson MC, O'Toole K, Cao Y, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol 1996;155:1557-62.
27. Diamandis EP, Yu H. Prostate cancer, prostate-specific antigen, and the polymerase chain reaction [Editorial]. Clin Chem 1995; 41:177-9.
28. Weiss L. Metastatic inefficiency: causes and consequences. Cancer Rev 1986;3:1-24.
29. Tarin D, Price JE, Kettlewell MGW, Souter RG, Vass ACR, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritovenous shunts. Cancer Res 1984;44:3584-92.
30. Koike A. Mechanism of blood-borne metastases. I. Some factors affecting lodgement and growth of tumor cells in the lungs. Cancer 1964;17:450-60.
31. Liotta LA, Kleinerman J, Saidel GM. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1982;45:44-53.
32. Rinker-Schaeffer CS, Partin AW, Isaacs WB, Coffey DS, Isaacs JT. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 1994;25: 249-65.
33. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1003.
34. Oesterling JE. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
35. Zarghami N, Diamandis EP. Detection of prostate-specific antigen mRNA and protein in breast tumors. Clin Chem 1996;42:361-6.
36. Levesque M, Yu H, D'Costa M, Diamandis EP. Prostate-specific, antigen expression by various tumors. J Clin Lab Anal 1995;9: 123-8.
37. Levesque M, Yu H, D'Costa M, Tadross L, Diamandis EP. Immunoreactive prostate-specific antigen in lung tumors. J Clin Lab Anal 1995;9:375-9.
38. Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994;78:1536-9.
39. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9: 1749-56.
40. Osborne MP, Rosen PP. Detection and management of bone marrow micrometastases in breast cancer. Oncology 1994;8:25-31.
41. Redding WH, Coombes RC, Monaghan P, Clink HM, Imrie SF, Dearnaley DP, et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983;ii:1271-4.
42. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534-9.
43. Güssow D, Rein R, Ginjaar I, Hochstenbach F, See G, Kottman A, Ploegh HL. The human β-2-microglobulin gene: primary structure and definition of the transcriptional unit. J Immunol 1987;139: 3132-8.
44. Qiu SD, Young CY, Bilhartz DL, Prescott JL, Farrow GM, He WW, Tindall DJ. In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 1990;144:1550-6.
45. Chelly J, Concordet JP, Kaplan JC, Kahn A. Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci USA 1989;86:2617-21.